All In Biotech

NDA 201370 · Pfizer

Heparin Sodium

Heparin Sodium · Injection

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jul 21, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,126

334 Phase 3, 112 recruiting

FAERS reports

14,058

11,053 serious, 2,653 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 3, 2025.

HEPARIN SODIUM INJECTION is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism; • Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation; • Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); • Prevention of clotting in arterial and cardiac surgery; • Prophylaxis and treatment of peripheral arterial embolism; • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. HEPARIN SODIUM INJECTION is an anticoagulant indicated for ( 1 ): • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prophylaxis and treatment of the thromboembolic complications associated with atrial fibrillation • Treatment of acute and chronic consumption coagulopathies • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Anticoagulant use in transfusion, extracorporeal circulation, and dialysis procedures

Mechanism: Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • HEPARIN SODIUM · HEPARIN SODIUM 1,000 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM PRESERVATIVE FREE · HEPARIN SODIUM 1,000 UNITS/ML · INJECTABLE, INJECTION · Prescription
  • HEPARIN SODIUM · HEPARIN SODIUM 5,000 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • HEPARIN SODIUM · HEPARIN SODIUM 10,000 UNITS/ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Heparin" as an intervention, any sponsor and status, largest first.

All 1,126 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • heparin-induced thrombocytopenia1,293
  • drug ineffective1,043
  • off label use787
  • nausea754
  • drug hypersensitivity643
  • vomiting620
  • hypotension571
  • dyspnoea558
  • pulmonary embolism519
  • sepsis503
  • pyrexia499
  • anaemia488

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004464
2005225
2006189
2007127
20081,029
2009247
2010472
2011403
2012356
2013329
2014276
2015367
2016402
2017527
2018642
2019796
2020705
2021975
20221,141
20231,251
20241,027
2025998
20261,110

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Heparin Sodium (Heparin Sodium,Porcine)

2024 spending

$2.4M

Beneficiaries

12,712

44,764 claims

Per beneficiary

$192

$2.01 per unit

View as table
YearSpending
2020$4,121,904
2021$3,265,769
2022$2,977,246
2023$2,796,464
2024$2,444,516

Part D: Heparin Sodium* (Heparin Sodium,Porcine/PF)

2024 spending

$36K

Beneficiaries

223

385 claims

Per beneficiary

$163

$6.39 per unit

View as table
YearSpending
2020$109,920
2021$66,886
2022$44,413
2023$33,516
2024$36,405

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,572 on PubMed

Sponsor: Pfizer · Also marketed as Heparin Sodium Preservative Free

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.